The present and future of peptide vaccines for cancer: Single or multiple, long or short, alone or in combination?

Cancer Journal

Volumn 17, Issue 5, 2011, Pages 343-350

  Slingluff, Craig L ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

cancer vaccine; immune therapy; melanoma; neoplasm; Peptide; TLR agonists; vaccine

Indexed keywords

CANCER VACCINE; CD40 ANTIGEN; DNA; IMMUNOLOGIC AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELAN A; PEPTIDE VACCINE; PHOSPHOPEPTIDE; RNA; TOLL LIKE RECEPTOR AGONIST;

CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; LYMPH NODE; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; T LYMPHOCYTE; TUMOR REGRESSION;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, CD274; ANTIGENS, CD4; ANTIGENS, CD40; CANCER VACCINES; EPITOPES; HUMANS; PHOSPHOPEPTIDES; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES; VACCINES, SUBUNIT;

EID: 80053343794     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318233e5b2     Document Type: Review

References (101)

1. Darrow TL, Slingluff CL Jr, Seigler HF. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens. J Immunol. 1989; 142:3329-3335. (Pubitemid 19129962)
2. Brinckerhoff LH, Thompson LW, Slingluff CL Jr. Melanoma vaccines. Curr Opin Oncol. 2000;12:163-173. (Pubitemid 32043959)
3. Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother. 2005;54:187-207. (Pubitemid 40174238)
4. Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, et al. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res. 2007; 13:6386-6395. (Pubitemid 350075028)
5. Slingluff CL Jr, Chianese-Bullock KA, Bullock TN, et al. Immunity to melanoma antigens: from self-tolerance to immunotherapy. Adv Immunol. 2006;90:243-295. (Pubitemid 43786236)
6. Speiser DE, Pittet MJ, Rimoldi D, et al. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumorspecific T cells. Semin Cancer Biol. 2003;13:461-472. (Pubitemid 38156138)
7. Rosenberg SA, Sherry RM, Morton KE, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigenspecific CD8+ T cells in patients with melanoma. J Immunol. 2005; 175:6169-6176. (Pubitemid 41508105)
8. Slingluff CL Jr, Petroni GR, Olson WC, et al. Effect of GM-CSF on circulating CD8+ and CD4+ T cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res. 2009;15:7036-7044.
9. Speiser DE, Lienard D, Rufer N, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005;115:739-746. (Pubitemid 40322250)
10. Slezak SL, Bettinotti M, Selleri S, et al. CMV pp65 and IE-1 T cell epitopes recognized by healthy subjects. J Transl Med. 2007;5:17.
11. Slingluff CL Jr, Petroni GR, Yamshchikov GV, et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol. 2004;22:4474-4485. (Pubitemid 41185113)
12. Yamshchikov GV, Barnd DL, Eastham S, et al. Evaluation of peptide vaccine immunogenicity in draining lymph nodes and blood of melanoma patients. Int J Cancer. 2001;92:703-711. (Pubitemid 32385714)
13. Chianese-Bullock KA, Pressley J, Garbee C, et al. MAGE-A1-, MAGEA10-, and gp100-derived peptides are immunogenic when combined with granulocyte- macrophage colony-stimulating factor and Montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. J Immunol. 2005;174:3080-3086. (Pubitemid 40279730)
14. Slingluff CL Jr, Petroni GR, OlsonW, et al. Helper T cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J Clin Oncol. 2008;26: 4973-4980.
15. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915. (Pubitemid 39273730)
16. Kirkwood JM, Lee S, Land S, et al. E1696: final analysis of the clinical and immunological results of a multicenter ECOG phase II trial of multi-epitope peptide vaccination for stage IV melanoma with MART-1 (27-35), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) (MGT) +/j IFNa2b and GM-CSF. J Clin Oncol (Meeting Abstracts). 2004;22:7502
17. Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A. 2002;99: 16168-16173. (Pubitemid 35462767)
18. Zippelius A, Batard P, Rubio-Godoy V, et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 2004;64:2865-2873. (Pubitemid 38500627)
19. Hamid O, Solomon JC, Scotland R, et al. Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Clin Cancer Res. 2007;13:215-222. (Pubitemid 46121871)
20. Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, et al. A randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. J Clin Oncol. 2011;29:2924-2932.
21. Chianese-Bullock KA, Lewis ST, Sherman NE, et al. Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies. Vaccine. 2009;27:1764-1770.
22. Baumgaertner P, Rufer N, Devevre E, et al. Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens. Cancer Res. 2006;66: 1912-1916.
23. Cox AL, Skipper J, Chen Y, et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science. 1994; 264:716-719. (Pubitemid 24185883)
24. Slingluff CL Jr, Yamshchikov G, Neese P, et al. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res. 2001;7:3012-3024. (Pubitemid 32963818)
25. Slingluff CL Jr, Colella TA, Thompson L, et al. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. Cancer Immunol Immunother. 2000;48:661-672. (Pubitemid 30146461)
26. Powell DJ Jr, Rosenberg SA. Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination. J Immunother. 2004;27:36-47. (Pubitemid 38076167)
27. Thompson LW, Garbee CF, Hibbitts S, et al. Competition among peptides in melanoma vaccines for binding to MHC molecules. J Immunother. 2004;27:425-431. (Pubitemid 39447350)
28. Mullins DW, Engelhard VH. Limited infiltration of exogenous dendritic cells and naive T cells restricts immune responses in peripheral lymph nodes. J Immunol. 2006;176:4535-4542.
29. Rosenberg SA, Sherry RM, Morton KE, et al. Altered CD8(+) T-cellresponses when immunizing with multiepitope peptide vaccines. J Immunother. 2006;29:224-231.
30. Fearon ER, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell. 1990;60:397-403.
31. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 1991;254:713-716. (Pubitemid 21917394)
32. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colonystimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci U S A. 1993;90:3539-3543. (Pubitemid 23111402)
33. Kast WM, Offringa R, Peters PJ, et al. Eradication of adenovirus E1- induced tumors by E1A-specific cytotoxic T lymphocytes. Cell. 1989; 59:603-614. (Pubitemid 19282867)
34. Greenberg PD, Riddell SR. Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol. 1995;13:545-586.
35. Kayaga J, Souberbielle BE, Sheikh N, et al. Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine. Gene Ther. 1999;6:1475-1481 [published erratum appears in Gene Ther. 1999;6:1905]. (Pubitemid 29396736)
36. Kahn M, Sugawara H, McGowan P, et al. CD4+ T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen. J Immunol. 1991;146:3235-3241.
37. Hunder NN, Wallen H, Cao J, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med. 2008;358:2698-2703. (Pubitemid 351860862)
38. Weiss WR, Sedegah M, Berzofsky JA, et al. The role of CD4+ T cells in immunity to malaria sporozoites. J Immunol. 1993;151:2690-2698. (Pubitemid 23264520)
39. Hung K, Hayashi R, Lafond-Walker A, et al. The central role of CD4+ T cells in the antitumor immune response. J Exp Med. 1998;188: 2357-2368. (Pubitemid 29028508)
40. Matsui S, Ahlers JD, Vortmeyer AO, et al. A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL. J Immunol. 1999;163: 184-193. (Pubitemid 29295840)
41. Pardoll DM, Topalian Sl. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol. 1998;10:588-594. (Pubitemid 28479193)
42. Na IK, Keilholz U, Letsch A, et al. Addition of GM-CSF to a peptide/ KLH vaccine results in increased frequencies of CXCR3-expressing KLH-specific T cells. Cancer Immunol Immunother. 2007;56:391-396. (Pubitemid 46035907)
43. Helling F, Zhang S, Shang A, et al. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res. 1995;55:2783-2788.
44. Scheibenbogen C, Schadendorf D, Bechrakis NE, et al. Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides. Int J Cancer. 2003;104:188-194. (Pubitemid 36249794)
45. Del Guercio MF, Alexander J, Kubo RT, et al. Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo. Vaccine. 1997;15:441-448. (Pubitemid 27157695)
46. Valmori D, Pessi A, Bianchi E, et al. Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination. J Immunol. 1992;149:717-721.
47. Demotz S. Delineation of several DR-restricted tetanus toxin T cell epitopes. J Immunol. 1989;142:394-402. (Pubitemid 19039954)
48. Slingluff CL Jr, Yamshchikov G, Neese P, et al. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res. 2001;7:3012-3024. (Pubitemid 32963818)
49. Topalian SL, Gonzales MI, Parkhurst M, et al. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DRYrestricted tyrosinase epitopes. J Exp Med. 1996;183:1965-1971. (Pubitemid 26158888)
50. Kobayashi H, Kokubo T, Sato K, et al. CD4+ T cells from peripheral blood of a melanoma patient recognize peptides derived from nonmutated tyrosinase. Cancer Res. 1998;58:296-301. (Pubitemid 28047070)
51. Zarour HM, Kirkwood JM, Kierstead LS, et al. Melan-A/MART- 1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci U S A. 2000;97:400-405. (Pubitemid 30055843)
52. Manici S, Sturniolo T, Imro MA, et al. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J Exp Med. 1999;189:871-876. (Pubitemid 29189692)
53. Chaux P, Vantomme V, Stroobant V, et al. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes [see comments]. J Exp Med. 1999;189:767-778.
54. Halder T, Pawelec G, Kirkin AF, et al. Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res. 1997;57:3238-3244. (Pubitemid 27351741)
55. Li K, Adibzadeh M, Halder T, et al. Tumour-specific MHC-class-IIY restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells. Cancer Immunol Immunother. 1998;47:32-38. (Pubitemid 28430528)
56. Khong HT, Yang JC, Topalian SL, et al. Immunization of HLA-A*0201 and/or HLA-DPbeta104 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J Immunother. 2004;27:472-477. (Pubitemid 39447355)
57. Phan GQ, Touloukian CE, Yang JC, et al. Immunization of patients with metastatic melanoma using both class IY and class-restricted peptides from melanoma-associated antigens. J Immunother. 2003;26: 349-356. (Pubitemid 36858719)
58. Wong R, Lau R, Chang J, et al. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma. Clin Cancer Res. 2004;10:5004-5013. (Pubitemid 39099774)
59. Lichterfeld M, Kaufmann DE, Yu XG, et al. Loss of HIV-1Yspecific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med. 2004;200: 701-712. (Pubitemid 39299457)
60. Phan GQ, Touloukian CE, Yang JC, et al. Immunization of patients with metastatic melanoma using both class IY and class-restricted peptides from melanoma-associated antigens. J Immunother. 2003;26:349-356. (Pubitemid 36858719)
61. Wong R, Lau R, Chang J, et al. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma. Clin Cancer Res. 2004;10:5004-5013. (Pubitemid 39099774)
62. Knutson KL, Schiffman K, Disis Ml. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest. 2001;107:477-484. (Pubitemid 32167994)
63. Slingluff CL Jr, Lee SJ, Chianese-Bullock KA, et al. First report of a randomized phase II trial of multi-epitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells in patients with metastatic melanoma: An Eastern Cooperative Oncology Group Study (E1602). J Clin Oncol. 2010;28. Abstract 8508.
64. Mohammed F, Cobbold M, Zarling AL, et al. Phosphorylationdependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self. Nat Immunol. 2008;9:1236-1243.
65. Depontieu FR, Qian J, Zarling AL, et al. Identification of tumorassociated, MHC class-restricted phosphopeptides as targets for immunotherapy. Proc Natl Acad Sci U S A. 2009;106:12073-12078.
66. Li Y, Depontieu FR, Sidney J, et al. Structural basis for the presentation of tumor-associated MHC class-restricted phosphopeptides to CD4+ T cells. J Mol Biol. 2010;399:596-603.
67. Slingluff CL Jr, Petroni GR, Smolkin ME, et al. Immunogenicity for CD8+ and CD4+ T cells of two formulations of an incomplete Freunds adjuvant for multipeptide melanoma vaccines. J Immunother. 2010;33: 630-638.
68. Rosenberg SA, Yang JC, Kammula US, et al. Different adjuvanticity of incomplete Freunds adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine. J Immunother. 2010;33:626-629.
69. Schaefer JT, Patterson JW, Deacon DH, et al. Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis. J Transl Med. 2010;8:79.
70. Overwijk W, Hailemichael Y, Dai Z, et al. Peptide/incomplete Freund adjuvant emulsion depots are a graveyard for tumor antigen-specific CD8+ T cells [abstract]. J Immunother. 2009;32:971
71. Zhu Q, Egelston C, Gagnon S, et al. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Invest. 2010;120:607-616.
72. Makela SM, Strengell M, Pietila TE, et al. Multiple signaling pathways contribute to synergistic TLR ligand-dependent cytokine gene expression in human monocyte-derived macrophages and dendritic cells. J Leukoc Biol. 2009;85:664-672.
73. Lore K, Betts MR, Brenchley JM, et al. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1Yspecific T cell responses. J Immunol. 2003;171:4320-4328. (Pubitemid 37238711)
74. Puggioni F, Durham SR, Francis JN, et al. (MPL) promotes allergeninduced immune deviation in favour of TH1 responses. Allergy. 2005; 60:678-684. (Pubitemid 40562476)
75. Mata-Haro V, Cekic C, Martin M, et al. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science. 2007; 316:1628-1632. (Pubitemid 46982038)
76. Peng G, Guo Z, Kiniwa Y, et al. Toll-like receptor 8Ymediated reversal of CD4+ regulatory T cell function. Science. 2005;309:1380-1384. (Pubitemid 41209366)
77. Zhu X, Fallert-Junecko BA, Fujita M, et al. Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners. Cancer Immunol Immunother. 2010;59:1401-1409.
78. CluffCW. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv Exp Med Biol. 2010;667:111-123.
79. Ahonen CL, Wasiuk A, Fuse S, et al. Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood. 2008;111:3116-3125.
80. Toes RE, Blom RJ, Offringa R, et al. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J Immunol. 1996;156:3911-3918. (Pubitemid 26139943)
81. Toes RE, Offringa R, Blom RJ, et al. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci U S A. 1996;93:7855-7860. (Pubitemid 26277128)
82. Srinivasan M, Domanico SZ, Kaumaya PT, et al. Peptides of 23 residues or greater are required to stimulate a high affinity class-restricted T cell response. Eur J Immunol. 1993;23:1011-1016. (Pubitemid 23120158)
83. Zwaveling S, Ferreira Mota SC, Nouta J, et al. Established human papillomavirus type 16Yexpressing tumors are effectively eradicated following vaccination with long peptides. J Immunol. 2002;169:350-358. (Pubitemid 34686155)
84. Sercarz EE, Maverakis E. MHC-guided processing: binding of large antigen fragments. Nat Rev Immunol. 2003;3:621-629. (Pubitemid 37328665)
85. BijkerMS, van den Eeden SJ, FrankenKL, et al. Superior induction of antitumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur J Immunol. 2008;38:1033-1042.
86. Janssen EM, Droin NM, Lemmens EE, et al. CD4+ T cell help helps control CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature. 2010;434:88-93. (Pubitemid 40349390)
87. Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361:1838-1847.
88. National Cancer Institute Immunotherapy Agent Workshop. Bethesda, MD. 12 July 2007.
89. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167-3175.
90. Sznol M, Powderly JD, Smith DC, et al. Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies. J Clin Oncol. 2010;28. Abstract 2506.
91. Fife BT, Pauken KE. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann N Y Acad Sci. 2011;1217:45-59.
92. Barber DL,Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439:682-687. (Pubitemid 43237609)
93. Bennett F, Luxenberg D, Ling V, et al. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokinedriven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. J Immunol. 2003;170:711-718. (Pubitemid 36070520)
94. Fife BT, Pauken KE, Eagar TN, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol. 2009;10:1185-1192.
95. Hirata S, Senju S, Matsuyoshi H, et al. Prevention of experimental autoimmune encephalomyelitis by transfer of embryonic stem cell-derived dendritic cells expressing myelin oligodendrocyte glycoprotein peptide along with TRAIL or programmed death-1 ligand. J Immunol. 2005;174:1888-1897. (Pubitemid 40223928)
96. Fife BT, Guleria I, Gubbels BM, et al. Insulin-induced remission in new-onset NOD mice is maintained by the PD-1YPD-L1 pathway. J Exp Med. 2006;203:2737-2747. (Pubitemid 44833349)
97. Higano CS, Schellhammmer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with Sipuleucel-T in advanced prostate cancer. Cancer. 2009;115:3670-3679.
98. Schwartzentruber DJ, Lawson D, Richards J, et al. A phase III multiinstitutional randomized study of immunization with the gp100: 209-217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma. J Clin Oncol. 2009;27. Abstract CRA9011.
99. Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364:2119-2127.
100. Faries MB, Hsueh EC, Ye X, et al. Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clin Cancer Res. 2009;15:7029-7035.
101. Lawson DH, Lee SJ, Tarhini AA, et al. E4697: phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma. J Clin Oncol. 2010;28. Abstract 8504.